全文获取类型
收费全文 | 85376篇 |
免费 | 41132篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 1619篇 |
儿科学 | 4465篇 |
妇产科学 | 588篇 |
基础医学 | 16690篇 |
口腔科学 | 5331篇 |
临床医学 | 12752篇 |
内科学 | 24870篇 |
皮肤病学 | 7706篇 |
神经病学 | 14013篇 |
特种医学 | 2407篇 |
外科学 | 15295篇 |
综合类 | 57篇 |
一般理论 | 21篇 |
预防医学 | 4240篇 |
眼科学 | 1372篇 |
药学 | 6142篇 |
中国医学 | 1029篇 |
肿瘤学 | 7957篇 |
出版年
2023年 | 53篇 |
2022年 | 93篇 |
2021年 | 1383篇 |
2020年 | 5091篇 |
2019年 | 10902篇 |
2018年 | 10194篇 |
2017年 | 11512篇 |
2016年 | 12179篇 |
2015年 | 12022篇 |
2014年 | 11926篇 |
2013年 | 12454篇 |
2012年 | 4380篇 |
2011年 | 4311篇 |
2010年 | 9042篇 |
2009年 | 5404篇 |
2008年 | 2255篇 |
2007年 | 1178篇 |
2006年 | 1207篇 |
2005年 | 1054篇 |
2004年 | 1020篇 |
2003年 | 1058篇 |
2002年 | 1172篇 |
2001年 | 1161篇 |
2000年 | 1127篇 |
1999年 | 655篇 |
1998年 | 164篇 |
1997年 | 136篇 |
1996年 | 122篇 |
1995年 | 119篇 |
1994年 | 96篇 |
1993年 | 83篇 |
1992年 | 305篇 |
1991年 | 288篇 |
1990年 | 255篇 |
1989年 | 240篇 |
1988年 | 198篇 |
1987年 | 222篇 |
1986年 | 181篇 |
1985年 | 186篇 |
1984年 | 138篇 |
1983年 | 110篇 |
1982年 | 48篇 |
1979年 | 107篇 |
1978年 | 71篇 |
1977年 | 61篇 |
1971年 | 58篇 |
1969年 | 45篇 |
1968年 | 54篇 |
1967年 | 44篇 |
1966年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
83.
84.
85.
86.
87.
Fardin Moradi Vahid Maleki Sevda Saleh‐Ghadimi Fatemeh Kooshki Bahram Pourghassem Gargari 《Clinical and experimental pharmacology & physiology》2019,46(11):975-983
Diabetes, as a low‐grade chronic inflammatory disease, causes disruption in proper function of immune and metabolic system. Chromium is an important element required for normal lipid and glucose metabolism. Chromium deficiency is correlated with elevation in cardiometabolic risk, which results from increased inflammation. This systematic review was conducted to discover the potential roles of chromium on inflammatory biomarkers. Eligible studies were all in vitro, animal and human studies published in English‐language journals from inception until October 2018. PubMed, Scopus, Embase, ProQuest and Google Scholar databases were searched to fined interventional studies from the effects of chromium on inflammatory biomarkers such as tumour necrosis factor a (TNF‐a), C‐reactive protein (CRP), interleukins, monocyte chemoattractant protein–1 (MCP‐1), intercellular adhesion molecule‐1 (ICAM‐1) and adipocytokines in hyperglycaemia and diabetes. Out of 647 articles found in the search, only 14 articles were eligible for analysis, three in vitro studies, eight animal studies and three human studies. Twelve of the 14 studies included in this review, chromium significantly decreased inflammatory factors. The findings of this review indicate, based on in vitro and in vivo studies, that chromium might have potential anti‐inflammatory properties, but some of the studies did not show anti‐inflammatory effects for chromium (two studies). There are only three studies in humans with controversial results. Therefore, more consistent randomized double‐blind controlled trials are needed to reach relevant clinical recommendations, as well as to determine the precise mechanism, of chromium on inflammation in diabetes. 相似文献
88.
89.
Three‐Dimensional Echocardiographic Evaluation of Mitral Apparatus during Preload Manipulation in Patients with Hypertrophic Cardiomyopathy 下载免费PDF全文
Hyemoon Chung M.D. Ji Hyun Yoon M.D. Young Won Yoon M.D. Ph.D. Ji Young Chung B.N. Jung‐Joon Cha M.D. Jong‐Youn Kim M.D. Ph.D. Pil‐Ki Min M.D. Ph.D. Byoung‐Kwon Lee M.D. Ph.D. Bum‐Kee Hong M.D. Ph.D. Se‐Joong Rim M.D. Ph.D. Hyuck Moon Kwon M.D. Eui‐Young Choi M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(8):1261-1269
90.
Stanislas Grassin‐Delyle Michaela Semeraro Frantz Foissac Naim Bouazza Haleema Shakur‐Still Ian Roberts Jean‐Marc Treluyer Saïk Urien 《Fundamental & clinical pharmacology》2019,33(6):670-678
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV. 相似文献